Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies

文化大學機構典藏 CCUR > 理工學院 > 理學院 > 生命科學系 > 期刊論文 > Item 987654321/44654

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://irlib.pccu.edu.tw/handle/987654321/44654

题名:	Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies
作者:	Lin, YL (Lin, Yu-Ling) Tsai, NM (Tsai, Nu-Man) Chen, CH (Chen, Chia-Hung) Liu, YK (Liu, Yen-Ku) Lee, CJ (Lee, Chung-Jen) Chan, YL (Chan, Yi-Lin) Wang, YS (Wang, Yu-Shan) Chang, YC (Chang, Yuan-Ching) Lin, CH (Lin, Chi-Hsin) Huang, TH (Huang, Tse-Hung) Wang, CC (Wang, Chao Ching) Chi, KH (Chi, Kwan-Hwa) Liao, KW (Liao, Kuang-Wen)
贡献者:	生命科學系
关键词:	CANCER-CELLS NANOPARTICLES POLYETHYLENIMINE TRASTUZUMAB PACLITAXEL LIPOSOMES CURCUMIN PEPTIDE BINDING GLYCOL
日期:	2019-02-06
上传时间:	2019-06-25 13:46:25 (UTC+8)
摘要:	BackgroundA cationic liposome-PEG-PEI complex (LPPC) was employed as a carrier for achieving targeted delivery of drug to human epidermal growth factor receptor-2 (HER2/neu)-expressing breast cancer cells. LPPC can be easily loaded with an anti-tumor drug and non-covalently associated with an anti-tumor antibody such as Herceptin that is clinically used to rapidly form immunoparticles within 1h.ResultsDrug-loaded LPPC have an average size about 250nm and a zeta potential of about 40mV. Herceptin was complexed onto surface of the LPPC to form the drug/LPPC/Herceptin complexes. The size of curcumin/LPPC/Herceptin complexes were 280nm and the zeta potentials were about 23mV. Targeting ability of this delivery system was demonstrated through specific binding on surface of cells and IVIS images in vivo, which showed specific binding in HER2-positive SKBR3 cells as compared to HER2-negative Hs578T cells. Only the drug/LPPC/Herceptin complexes displayed dramatically increased the cytotoxic activity in cancer cells. Both in vitro and in vivo results indicated that Herceptin adsorbed on LPPC directed the immunocomplex towards HER2/neu-positive cells but not HER2/neu-negative cells. The complexes with either component (curcumin or doxorubicin) used in the LPPC-delivery system provided a better therapeutic efficacy compared to the drug treatment alone and other treatment groups, including clinical dosages of Herceptin and LipoDox, in a xenografted model.ConclusionsLPPC displays important clinical implications by easily introducing a specific targeting characteristic to drugs utilized for breast cancer therapy.
關聯:	Journal of Nanobiotechnology volume 17, Article number: 25 (2019)
显示于类别:	[生命科學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	167	检视/开启

检视Licence

在CCUR中所有的数据项都受到原著作权保护.

数据加载中.....